a, b, HSP70 mRNA level in iWAT explants from DIO mice 24 hr after, vehicle (n=41) vs. TubA (n=42, P=1.1E-3) (a) or Vehicle (n=4) vs. CAY10603 (n=4, P=3.8E-4, by two-tailed unpaired t-test for a and b) (b) treatments. c, HSP25 and HSP70 mRNA expression in 293T cells transfected with the indicated constructs (n=6. HSP25: GFP vs. HDAC6CI P=1.5E-9, HDAC6 WT vs. HDAC6CI P=2.8E-9; HSP70: GFP vs. HDAC6CI P=3E-5, HDAC6 WT vs. HDAC6CI P=4.5E-9, GFP vs. HDAC6 WT P=3.1E-5). d, TSC2+/+ and TSC−/− mouse embryonic fibroblasts (MEFs) were treated with vehicle (DMSO) or celastrol for 24 hr. Cell lysates were analyzed by immunoblots. The results were confirmed in three independent experiemnts e, p-PERK and total PERK protein levels in liver homogenates from wild-type DIO mice treated with vehicle or celastrol. Th experiment was conducted in two independent cohorts of mice with similar outcomes. Data are represented as mean ± s.e.m.